๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases

โœ Scribed by Eduardo Maldonado-Gonzales; Peter Pietschmann

Publisher
Springer Vienna
Year
2010
Tongue
German
Weight
158 KB
Volume
160
Category
Article
ISSN
0043-5341

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Receptor activator of nuclear factor-ฮบB
Receptor activator of nuclear factor-ฮบB ligand and osteoprotegerin : Potential implications for the pathogenesis and treatment of malignant bone diseases
โœ Lorenz C. Hofbauer; Andreas Neubauer; Armin E. Heufelder ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 142 KB ๐Ÿ‘ 1 views

## Background: The current review summarizes the roles of the ligand, receptor activator of nuclear factor-kappab ligand (rankl), its receptor, receptor activator of nuclear factor-kappab (rank), and its decoy receptor, osteoprotegerin (opg), on osteoclast biology and bone resorption. furthermore,

Monoclonal antibody DLC-48: An effective
Monoclonal antibody DLC-48: An effective reagent for use in the depletion of malignant lymphoma from human bone marrow
โœ Jane N. Winter; Robert J. Marder; James A. Radosevich; Alan L. Epstein ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 891 KB

A combination of large-cell lymphoma cell lines was used as immunogen in the production of DLC-48, a mouse monoclonal antibody (MAb) to a B-cell-associated antigen. This reagent identifies a protein found on a majority of peripheral blood B-cells, B-cell derived tumor cell lines, and lymphoma biopsy